@article{e73c9ea806304ee0a945ae3403f6d801,
title = "An analysis of research biopsy core variability from over 5000 prospectively collected core samples",
abstract = "Factors correlated with biopsy tissue adequacy and the prevalence of within-biopsy variability were evaluated. Totally, 1149 research biopsies were performed on 686 patients from which 5090 cores were assessed. Biopsy cores were reviewed for malignant percentage (estimated percentage of cells in the core that were malignant) and malignant area (estimated area occupied by malignant cells). Linear mixed models and generalized linear mixed models were used for the analysis. A total of 641 (55.8%) biopsies contained a core with <10% malignant percentage (inadequate core). The chance of an inadequate core was not influenced by core order, though the malignant area decreased with each consecutive core (p < 0.001). Younger age, bone biopsy location, appendiceal tumor pathology, and responding/stable disease prior to biopsy increased the odds of a biopsy containing zero adequate cores. Within-biopsy variability in core adequacy is prevalent and suggests the need for histological tumor quality assessment of each core in order to optimize translational analyses.",
author = "Deepak Bhamidipati and Anuj Verma and Dawen Sui and Dipen Maru and Grace Mathew and Wenhua Lang and Juan Posadas and Joshua Hein and Scott Kopetz and Andrew Futreal and Wistuba, {Ignacio I.} and Sanjay Gupta and Lee, {J. Jack} and Overman, {Michael J.} and Tam, {Alda L.}",
note = "Funding Information: M.O. has received honoraria from Roche, Bristol Meyers Squibb, Medimmune, and Celgene, and has served as a consultant or adviser to Roche, Bristol Meyers Squibb, Medimmune, Merck, and Amgen. A.T. has received research funding from Boston Scientific and Guerbet and has served as a consultant or adviser to Boston Scientific and Cello Therapeutics, Inc. I.W. reports grants and personal fees from Genentech/ Roche, Bayer, Bristol-Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Merck, GlaxoSmithKline, Guardant Health, and MSD; grants from Oncoplex, DepArray, Adaptive, Adaptimmune, EMD Serono, Takeda, Amgen, Karus, Johnson & Johnson, Iovance, 4D, Novartis, Oncocyte, and Akoya; personal fees from Flame. The remaining authors declare no competing interests. Funding Information: The authors acknowledge the contribution of Kelly Kage, MFA, CMI, for her assistance with the medical graphics in this article and Isha Khanduri for providing representative photomicrographs of the core biopsies. This work was supported through the National Cancer Institute through the Cancer Center Support Grant P30CA16672, SPORE Grant P50CA221707 and supported by the generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Moon Shots Program{\texttrademark} as well as the Adaptive Patient-Oriented Longitudinal Learning and Optimization (APOLLO) platform. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
month = dec,
doi = "10.1038/s41698-021-00234-8",
language = "English (US)",
volume = "5",
journal = "npj Precision Oncology",
issn = "2397-768X",
publisher = "Springer Nature",
number = "1",
}